The iStent® is the first minimally invasive FDA-approved implantable device for the treatment of open angle glaucomas. The iStent ® is a Micro-Invasive Glaucoma Surgery (MIGS) approved to be done in conjunction with cataract surgery. Since it is done at the same time as cataract surgery, no additional incisions are necessary. The surgical procedure involves placement of a tiny 1mm long titanium devicethrough the trabecular meshwork and into Schlemm's canal to enhance aqueous outflow from the anterior chamber and lower intraocular pressure.
Who is a good candidate for iStent® Trabecular Micro-bypass?
iStent® is indicated for the surgical treatment of mild to moderate open angle glaucomas. It is contraindicated in patients with primary or secondary angle closure glaucoma, neovascular glaucoma, patients with thyroid eye disease, retrobulbar tumors, Sturge-Weber Syndrome, and/or any other condition causing elevated episcleral venous pressure.
How does the iStent® Trabecular Micro-bypass work?
The iStent® reduces IOP by increasing outflow through the trabeculocanalicular outflow pathway. It increases the flow of aqueous humor from the anterior chamber, directly into Schlemm's canal, and out through the collector channels. This procedure does not create a 'bleb' on the surface of the eye as fluid is routed through normal physiological pathways. .
This procedure does not involve opening up the conjunctival tissues to access Schlemm's canal. This is a major advantage of this procedure as it makes future glaucoma surgery (if needed) a lot simpler with less risk of failure.